INMB earnings analysis
What we found in INMB's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
INmune Bio's Q4 2026 results showed no reported revenue, following a previous quarter revenue of $50,000. The company reported a reduced net loss of $5.4 million compared to a loss of $9.7 million in the same quarter last year, indicating improved cost management and lower research expenses.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Improved EPS Over Prior Year
- Diluted EPS improved to -$0.18 from -$0.24 a year ago, reflecting a positive trend.
- Reduction in Operating Expenses
- Total operating expenses decreased to $5.8 million from $9.95 million in the prior year, a reduction of $4.14 million.
- Higher Cash Balance
- Cash and cash equivalents stood at $21.4 million, down from $24.8 million at the end of 2025, indicating a manageable liquidity position.
- Lower Research and Development Costs
- R&D expenses dropped significantly to $3.641 million from $7.639 million year-over-year, due to completion of certain trials.
- Increase in Other Income
- Other income increased to $0.4 million for Q1 2026, compared to $0.2 million in Q1 2025, suggesting better financial management.
- Sustained Operational Improvements
- Net cash used in operating activities decreased to $3.4 million from $6.8 million year-on-year.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Ongoing Losses Concerning
- Net loss of $5.4 million indicates continuing operational struggles despite progress.
- Capital Requirement Risks
- Substantial doubt regarding ability to continue as a going concern due to anticipated losses and funding needs is emphasized.
- Regulatory Approval Dependencies
- Continued delays or failures in receiving regulatory approvals for products could significantly impact future revenues.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.18
What they said about what is next.
Management suggests continued losses will persist; future financial condition remains uncertain.
The filing reads better than the one before it.
What came before.
- 10-K · March 30, 2026
- INmune Bio is a clinical‑stage biotech focused on reprogramming innate immunity, with lead asset CORDStrom completing a pivotal blinded randomized cross‑over trial and the company targeting MAA filings in the UK/EU…
- 10-Q · August 7, 2025
- INmune Bio's Q2 2025 results reveal significant continued losses, with actual revenue reported at $0.0 and a net loss of $24.5 million, resulting in a diluted EPS of -$1.05, down from -$0.50 in Q2 2024. Cash reserves…
- 10-Q · October 31, 2024
- INmune Bio reported Q3 2024 net loss of $12,093,000 (‑$0.60/share) on revenue of $0, widening from Q3 2023 net loss of $8,563,000 (‑$0.48/share). R&D spending accelerated to $10,067,000 in the quarter (vs. $5,985,000…
- 10-Q · November 1, 2023
- INmune Bio reported Q3 revenue of $43,000 (down from $98,000 in Q3 2022) and GAAP net loss of $8,563,000 (EPS $(0.48)) for the quarter. Operating expenses increased to $8,571,000 in the quarter, cash declined to…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing INMB makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever